written on 03.06.2014
Tags:
,

Boehringer Ingelheim, Eli Lilly can resubmit NDA for diabetes drug with warning letter resolved

TAGS: ,

Boehringer Ingelheim has finally received some good news for its manufacturing facility in Ingelheim, Germany. The FDA has notified it that it has closed out a warning letter for the facility.

Latest Report